The extent to which the observed neuroprotective effects are specific for SAHA and hence the inhibition of xCT expression with reduced glutamate secretion was further examined in another experiment utilizing the HDAC inhibitor MS-275, which does not induce xCT suppression in malignant gliomas (Fig. 3A). Here, HDAC9 is linked to malignant glioma.